Inclusion Criteria:~* NINCDS/ADRDA criteria for probable AD~* MMSE between 12-27~* Treatment with a
cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks~*
Home monitoring available for supervision of medications~* Caregiver available to accompany patient to all
visits and willing to participate in study as informant~* Fluent in English or Spanish~* Medical stability for
this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory
tests~* Stable doses of non-excluded medication~* No evidence of hepatic insufficiency~* Able to swallow oral
medications~* Ability to participate in the informed consent process~
